X-linked lymphoproliferative syndrome, EBV infection and impaired regulation of cell-mediated cytotoxicity;Sindrome linfoproliferativo ligado al cromosoma X, infeccion por el virus EBV y defectos en la regulacion de la citotoxicidad linfocitaria

Medicina

Volumn 63, Issue 1, 2003, Pages 70-76

  Malbran, Alejandro ^a   Belmonte, Liliana ^b   Ruibal Ares, Beatriz ^b   Bare, Patricia ^b   Bracco, Maria Marta E ^b  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b INST DE INVEST HEMATOLOGICAS   (Argentina)

Author keywords

2B4; EBV; NK activity; SAP; SLAM; XLP

Indexed keywords

CD150 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; REGULATOR PROTEIN; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEDIATED CYTOTOXICITY; DISEASE ASSOCIATION; EFFECTOR CELL; EPSTEIN BARR VIRUS; FATALITY; GENE ACTIVATION; GENE MUTATION; GENETIC CODE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTIOUS MONONUCLEOSIS; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; PATHOGENESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL; T LYMPHOCYTE; VIRUS INFECTION; X CHROMOSOME LINKAGE;

ANTIGENS, CD; CARRIER PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; GLYCOPROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037251817     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Purtilo DT, Cassel CK, Yung JPS, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1: 935-41.
2. Hamilton JK, Paquin LA, Sullivan JL, et al. X-Linked lymphoproliferative syndrome registry report. J Pediatrics 1980; 96: 669-73.
3. Sullivan JL, Byron KS, Brewster FE, Baker SM, Ochs HD. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. J Clin Invest 1983; 71: 1765-78.
4. Seemayer TA, Gross TG, Maarten-Egeler R, et al. X-linked lymphoproliferative disease: twenty-five years after discovery. Pediat Res 1995; 38: 471-78.
5. Ruibal-Ares B, Belmonte L, Baré P, et al. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients. J Human Virol 2001; 4: 200-13.
6. Arico M, Imashuku S, Clementi R, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001; 97: 1131-3.
7. Sumazaki R, Kanegane H, Osaki M, at al. SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood 2001; 98: 1268-70.
8. Morra M, Silander O, Calpe S, et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001; 98: 1321-5.
9. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, et al., eds. Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996, pp 2343-96.
10. Rickinson AB, Rowe M, Hart IJ, et al. T-cell-mediated regresion of spontaneous and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin-A. Cell Immunol 1984; 87: 646-58.
11. Vajro P, Lucariello S, Migliaro F, et al. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis 2000; 181: 2050-54.
12. Pelicci PG, Knowles DM, Arlin ZA, et al. Monoclonal B cell expansions and c-myc rearrangements in acquired immunodeficiency syndrome-related lymphoproliferative disorders: implications for lymphomagenesis. J Exp Med 1986; 164: 2049-76.
13. O'Reilly RJ. Biology and adoptive cell-therapy of Epstein-Barr virus infection in T-cell immunocompromised individuals. J Virol 1996; 70: 4884-94.
14. Cocks BG, Chang CC, Carballido JM, Issel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995; 376: 260-3.
15. Aversa G, Chang CC, Carballido JM, Cocks BG, de Vries JE. Engagement of the signaling lymphocyte activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A sensitive T cell proliferation and IFNγ production. J Immunol 1997; 158: 4036-44.
16. García VE, Quiroga MF, Ochoa MT, et al. Signaling lymphocyte activation molecule expresión and regulation in human intracellular infection, correlate with Th1 patterns. J Immunol 2001; 167: 5719-24.
17. Quiroga MF, Pasquinelli V, Fainboim L, Garcia VE. Expresión y regulación de SLAM (molécula linfocitaria activadora de señales) en la infección humana intracelular. Medicina (Buenos Aires) 2001; 61: 715.
18. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in the SH2 domain encoding gene. Nature Genet 1998; 20: 120-35.
19. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in a SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998; 95: 13765-70.
20. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals through the co-receptor SLAM . Nature 1998; 395: 462-9.
21. Lewis J, Eiben LJ, Nelson DL, et al. Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family. Clin Immunol 2001; 100: 15-23.
22. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative-disease gene product. Nature Immunol 2001; 2: 681-90.
23. Wu C, Nguyen KB, Pien GC, et al. SAP controls T cell responses to virus and terminal differentiation of Th2 cells. Nature Immunol 2001; 2: 410-14.
24. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Human 2B4, an activating NK cell receptor, recruits the proteine tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999; 162: 6981-5.
25. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative síndrome. J Immunol 2000; 165: 2932-6.
26. Parolini S, Bottino C, Falco M, et al. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr-virus-infected cells. J Exp Med 2000; 3: 337-46.
27. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 2000; 165: 3549-53.
28. Speiser DE, Colonia M, Ayyoub M, et al. The activation receptor 2B4 is expressed in vivo by human CD8 effector αβT cells. J Immunol 2001; 167: 6165-70.
29. Castro AG, Hauser TM, Cocks BG, et al. Molecular and functional characterization of mouse SLAM: differential expresion and responsiveness in Th1 and Th2 cells. J Immunol 1999; 163: 5860-70.
30. Nichols KE, Koretzky GA, June CH. SAP: natural inhibitor or grand SLAM of T cell activation? Nature Immunol 2001; 2: 665-6.
31. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. GAT is a natural killer cell? Nature Immunol 2002; 3: 6-8.
32. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opinion Immunol 2001; 13: 458-64.
33. Nakajima H, Cella M, Bouchon A, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000; 30: 3309-18.
34. Brown MH, Boles K, van der Mewe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein is a ligand of CD48. J Exp Med 1998; 188: 2083-90.
35. Chuang SS, Kumaresan PR, Mathew PH. 2B4 (CD244)-mediated activation of cytotoxicity and IFNγ release in human NK cells involves distinct pathways. J Immunol 2001; 167: 6210-6.
36. Kambayashi T, Assarsson E, Chambers BJ, Ljunggren H-G. Regulation of CD8+ T cell proliferation by 2B4/CD48 interactions. J Immunol 2001; 167: 6706-10.
37. Latchman Y, McKay PF, Reiser H. Identification of the 2B4 molecule as a counter-receptor for CD48. J Immunol 1998; 161: 5809-12.
38. Thorley-Lawson DA, Ianelli C, Klaman LD, Staunton D, Yokohama S. Function of CD48 and its regulation by Epstein-Barr virus. Biochem Soc Trans 1993: 21: 976-80.